|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-1-22
|
|
pubmed:abstractText |
The clinical activity of rituximab, a chimeric monoclonal antibody which binds to the CD20 antigen, was evaluated as a single first-line therapy for patients with follicular non-Hodgkin lymphoma (NHL). Fifty patients with follicular CD20(+) NHL and a low tumor burden were analyzed for clinical and molecular responses. They received 4 weekly infusions of rituximab at a dose of 375 mg/m(2). The response rate a month after treatment (day 50) was 36 of 49 (73%), with 10 patients in complete remission, 3 patients in complete remission/unconfirmed, and 23 patients in partial remission. Ten patients had stable disease, and the disease progressed in 3 patients. One of 13 (8%) patients in complete remission, 9 of 23 (39%) patients in partial remission, and 5 of 10 (50%) patients with stable disease exhibited disease progression during the first year. Within the study population, 32 patients were initially informative for polymerase chain reaction (PCR) data on bcl-2-J(H) rearrangement. On day 50, 17 of 30 patients (57%) were negative for bcl-2-J(H) rearrangement in peripheral blood, and 9 of 29 (31%) were negative in bone marrow; a significant association was observed between molecular and clinical responses (P <.0001). At month 12, 16 of 26 patients (62%) were PCR negative in peripheral blood. These results indicate that early molecular responses can be sustained for up to 12 months and that this response is highly correlated with progression-free survival. Rituximab has a high clinical activity and a low toxicity and induces a high complete molecular response rate in patients with follicular lymphoma and a low tumor burden.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:BenzohraAA,
pubmed-author:BouéFF,
pubmed-author:BrousseNN,
pubmed-author:ColombatPP,
pubmed-author:DeconinckEE,
pubmed-author:DelwailVV,
pubmed-author:EftekhariPP,
pubmed-author:FoussardCC,
pubmed-author:HaïounCC,
pubmed-author:LederlinPP,
pubmed-author:Mathieu-BouéAA,
pubmed-author:MilpiedNN,
pubmed-author:MontestrucFF,
pubmed-author:NajmanAA,
pubmed-author:SallesGG,
pubmed-author:SebbagDD,
pubmed-author:Solal-CélignyPP,
pubmed-author:SoubeyranPP,
pubmed-author:StamatoullasAA,
pubmed-author:TaillanBB,
pubmed-author:ThièblemontCC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
101-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11133748-Adolescent,
pubmed-meshheading:11133748-Adult,
pubmed-meshheading:11133748-Aged,
pubmed-meshheading:11133748-Antibodies, Monoclonal,
pubmed-meshheading:11133748-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:11133748-Antigens, CD20,
pubmed-meshheading:11133748-Antineoplastic Agents,
pubmed-meshheading:11133748-Disease Progression,
pubmed-meshheading:11133748-Female,
pubmed-meshheading:11133748-Follow-Up Studies,
pubmed-meshheading:11133748-Gene Rearrangement,
pubmed-meshheading:11133748-Genes, bcl-2,
pubmed-meshheading:11133748-Humans,
pubmed-meshheading:11133748-Immunoglobulin Joining Region,
pubmed-meshheading:11133748-Lymphoma, Follicular,
pubmed-meshheading:11133748-Male,
pubmed-meshheading:11133748-Middle Aged,
pubmed-meshheading:11133748-Polymerase Chain Reaction,
pubmed-meshheading:11133748-Remission Induction,
pubmed-meshheading:11133748-Time Factors,
pubmed-meshheading:11133748-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
|
|
pubmed:affiliation |
CHU Bretonneau, Tours, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
